Login to Your Account

Chimerix Aiming to ‘SUPPRESS’ CMV Infection in Phase III

By Jennifer Boggs
Managing Editor

Tuesday, September 10, 2013
Only a few months after its impressive Nasdaq debut, antiviral firm Chimerix Inc. started dosing in its Phase III SUPPRESS trial testing oral nucleotide analogue lipid-conjugate brincidofovir (CMX001) for the prevention of cytomegalovirus (CMV) infection in hematopoietic cell transplant recipients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription